MET and head and neck squamous cell carcinoma: However, a previously published study demonstrated that the c-MET targeting agent crizotinib does not increase the efficiency of irradiation in HNSCC xenograft tumors that originate from UT-SCC-14 and UT-SCC-15 cells [64].